Cite
HARVARD Citation
Persson, F. et al. (2018). Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study. Diabetes, obesity & metabolism. 20 (2), pp. 344-351. [Online].